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A B S T R A C TObjective: Invasive pneumococcal disease is a major cause of preven-
table morbidity and mortality in the United States, particularly among
the elderly (465 years). There are large racial disparities in pneumococcal
vaccination rates in this population. Here, we estimate the cost-
effectiveness of a hypothetical national vaccination intervention program
designed to eliminate racial disparities in pneumococcal vaccination in
the elderly. Methods: In an exploratory analysis, a Markov decision-
analysis model was developed, taking a societal perspective and assum-
ing a 1-year cycle length, 10-year vaccination program duration, and
lifetime time horizon. In the base-case analysis, it was conservatively
assumed that vaccination program promotion costs were $10 per
targeted minority elder per year, regardless of prior vaccination status
and resulted in the elderly African American and Hispanic pneumococcal
vaccination rate matching the elderly Caucasian vaccination rate (65%) insee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.11.009
dis.constant@medstudent.pitt.edu.
ondence to: Constantinos I. Michaelidis, Universityyear 10 of the program. Results: The incremental cost-effectiveness of
the vaccination program relative to no program was $45,161 per quality-
adjusted life-year gained in the base-case analysis. In probabilistic
sensitivity analyses, the likelihood of the vaccination program being
cost-effective at willingness-to-pay thresholds of $50,000 and $100,000
per quality-adjusted life-year gained was 64% and 100%, respectively.
Conclusions: In a conservative analysis biased against the vaccination
program, a national vaccination intervention program to ameliorate
racial disparities in pneumococcal vaccination would be cost-effective.
Keywords: cost-effectiveness, disparities, invasive pneumococcal
disease, vaccination.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Invasive pneumococcal disease (IPD) is a major cause of mor-
bidity and mortality in the United States, causing 40,000 hospi-
talizations and 4,000 deaths annually [1]. Elderly populations are
particularly vulnerable, with greater than 30% of IPD-attributable
hospitalizations and 50% of IPD-attributable deaths occurring in
this group [2].
The 23-valent pneumococcal polysaccharide vaccine (PPSV23)
prevents IPD and is universally recommended at age 65 years in
the United States [3,4]. Current pneumococcal vaccination rates
in the elderly, however, remain far below the 90% goal set by the
Healthy People 2010 objective, with substantial racial disparities;
only 65% of Caucasians, 45% of African Americans, and 40% of
Hispanics in this age group reported having ever received pneu-
mococcal vaccination in 2009 [5]. Racial vaccination disparities
are particularly concerning given significantly higher IPD inci-
dence in African American, Hispanic, and Native-American
populations [2,6–8].
Prior research suggests that national programs to reduce
disparities in influenza vaccination in elderly minorities can be
cost-effective [9]. This work, however, has not been extended topneumococcal vaccination and, thus, it remains unclear as to
whether a program to reduce disparities in pneumococcal vacci-
nation would also be cost-effective. Here, a Markov decision-
analysis model was used to assess the cost-effectiveness of a
hypothetical national vaccination intervention program designed
to eliminate known racial disparities in pneumococcal vaccina-
tion rates in the elderly. The goal of this exploratory analysis was
to quantify broad cost and effectiveness parameters that a cost-
effective vaccination program would need to satisfy, and not to
specifically delineate program parameters.Methods
Perspective and Model Cohort
In the base-case analysis, a societal perspective was taken,
including both direct medical and direct nonmedical costs and
following the reference case recommendations of the US Panel
on Cost-Effectiveness in Health and Medicine [10]. The model
cohort was the combined 2006 US 65-year-old African-American
and Hispanic birth cohort. We assumed that individuals hadSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – The Markov state transition diagram. The only
differences between the intervention and no-intervention
arms of the model are the cost of the vaccination program
and the probability of receiving pneumococcal vaccination
in every Markov cycle.
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was no residual IPD protective immunity.
Model Structure
To estimate the cost-effectiveness of a hypothetical US national
vaccination intervention program to eliminate racial disparities
in pneumococcal vaccination rates, a Markov decision-analysis
model was developed by using TreeAge Pro 2009 (TreeAge Soft-
ware, Inc., Williamstown, MA). The model used a 1-year cycle
length and a lifetime time horizon, examining a 10-year vaccina-
tion intervention program. The 10-year program duration allowed
for assumptions regarding declining program impact on popula-
tion vaccination rates and declining vaccination-related IPD
immunity with time. In both the intervention and no-
intervention arms of the model, the target population began in
a well (-unvaccinated) health state and transitioned to well
(-vaccinated), IPD, disabled, or dead health states on the basis
of annual probabilities of receiving vaccination, acquiring IPD,
becoming disabled because of IPD, or dying because of IPD or
other causes (Fig. 1). Annual mortality rates due to other causes
were modeled on the basis of 2006 US mortality tables [11]. Given
little data on the likelihood of disability with IPD, we used IPD
meningitis rates as a proxy, understanding that not all meningitis
leads to disability and that other forms of IPD can. We assumedTable 1 – Epidemiology of invasive pneumococcal diseas
IPD cases per 100,000 per year in the general population (all races)
African American population
Hispanic population
African American, Hispanic weighted average
IPD outcomes per 100,000 per year in the general population (all races)
IPD meningitis
IPD death
PPSV23 vaccine serotype coverage (all races)
Population immunocompromised (all races)
ABCs, Active Bacterial Core surveillance network; PPSV23, 23-valent pne
 Estimates of race-level IPD incidence do not include corrections for pr
y Based on ABCs population-level data on the incidence of IPD in the Af
z Based on relative incidence of IPD in African American and Hispanic p
§ Based on incidence of IPD in African American and Hispanic elderly pthat all IPD cases were hospitalized and did not first seek
outpatient care, biasing the model against the vaccination pro-
gram [2]. The only differences between the model arms were
vaccination program costs and the probability of vaccination in
model years 1 to 10.IPD Incidence, Disability, and Mortality
Age-specific estimates of IPD incidence, disability (meningitis),
mortality, vaccine serotype coverage, and the likelihood of
immunocompromising conditions were obtained from 2007-
2008 Active Bacterial Core surveillance data (Table 1). As IPD
incidence—but not IPD case fatality—is known to vary by race,
race-specific estimates of IPD incidence were incorporated
[2,6–8]. African American IPD incidence was estimated by assum-
ing that the proportion of IPD cases for each African American
age cohort was the same as the proportion of IPD cases for each
age cohort in the entire elderly population. This assumption was
tested in sensitivity analyses in which IPD incidence was varied
from 80% to 120% of the base-case value to examine model
robustness when this assumption was relaxed. Lacking empirical
data, we estimated IPD incidence in Hispanics on the basis of
relative incidence rates of IPD in African American and Hispanic
pediatric populations (relative risk 1.22:1) [7]. Because these are
pediatric literature data, a secondary analysis was performed in
which the relative IPD risk in these populations was varied from
80% to 120% of the base-case value, based on author estimates, to
account for possible differences between pediatric and elderly
cohorts. A population-weighted average IPD incidence was then
estimated from the elderly African American and Hispanic
populations on the basis of the relative size of these two
populations (ratio 1.49:1) [12]. This IPD incidence estimate is in
part a function of current pneumococcal vaccination uptake and
thus likely underestimates IPD incidence when the theoretical
absence of PPSV23 is modeled. To account for current pneumo-
coccal vaccination effects on IPD incidence rates, elderly African
American and Hispanic IPD rates were adjusted on the basis of
data from a previous study suggesting that PPSV23 had led to IPD
incidence reductions of 27.8, 13.5, 11.0, 1.7, and 3.4%, respectively,
in the 65 to 69, 70 to 74, 75 to 79, 80 to 84, and 85 years and older
age cohorts across races (Table 1) [13]. We elected not to model
changes in herd immunity for several reasons. First, the elderly
IPD incidence rate has been stable from 2005 to 2010 [1,14].
Second, it is difficult to predict the impact of the recentlye (IPD) in the US elderly population, 2007–2008.
Age cohorts (y)
65–69 70–79 Z80 Source
25.9 33.9 60.1 ABCs
41.6 54.5 96.4 Estimatey
34.0 44.6 78.9 Estimatez
38.5 50.5 89.3 Estimate§
1.6 1.3 1.3 ABCs
2.9 3.9 11.9 ABCs
74.1% 65.8% 62.9% ABCs
13.1% 20.2% 23.8% ABCs
umococcal polysaccharide vaccine.
ior vaccination status explained in the text.
rican American population.
ediatric populations [7].
opulations and relative population sizes [12].
Table 2 – Parameter values for base-case and sensitivity analyses.
Parameter range
Description Base Low High Distribution Source
Probabilities
African American, proportion in minority cohort 0.40 Not varied Not varied Not varied 12
Hispanic, proportion in minority cohort 0.60 Not varied Not varied Not varied 12
IPD incidence Table 1 6.6% þ6.6% Triangular 1
IPD disability Table 1 17.5% þ17.5% Triangular 1
IPD mortality Table 1 16.3% þ16.3% Triangular 1
Percentage of elderly immunocompromised Table 1 11.7% þ11.7% Triangular 1
PPSV23 serotype coverage Table 1 6.3% þ6.3% Triangular 1
Vaccine effectiveness (year post vaccination) Triangular 27
Year 1 0.80 0.60 0.90
Year 3 0.73 0.50 0.83
Year 5 0.58 0.31 0.80
Year 7 0.33 0.13 0.48
Year 10 0.00 0.00 0.10
Year 15 0.00 0.00 0.10
Change in vaccine effectiveness due to race Base 10% þ10% Triangular Estimate
Vaccination rate with no program (cumulative)
Elderly African American population 0.45 Not varied Not varied Not varied 5
Elderly Hispanic population 0.40 Not varied Not varied Not varied 5
Vaccination rate with program (cumulative) Figure 2 Figure 2 Figure 2 Triangular Estimate
Vaccine side effectsy 0.03 0.02 0.05 Beta 28
Excess mortality due to disability (per year) 0.1 0.0 1.0 Triangular 29
Costs ($)
Program, per targeted elder per year 10 5 15 Triangular 9
Pneumococcal vaccine and administration 33.47 16.74 55.79 Gamma 29
Treatment of vaccine side effects 0.50 0.25 0.75 Gamma Estimate
IPD
Hospitalization without death 27,357 25,224 30,093 Gamma 29
Hospitalization with death 37,688 33,919 41,458 Gamma 29
Disability (annual) 12,683 10,451 14,914 Gamma 30
Durations
Vaccine side effects (d) 3 1 8 Gamma 28
IPD hospitalization (d) 12 9 15 Gamma 31
Utilities
One year of healthy life for465-y-olds (QALY) Uniform 21, 32
65–70 y 0.76 0.71 0.81
70–75 y 0.74 0.69 0.79
75–80 y 0.70 0.65 0.75
80–85 y 0.63 0.58 0.68
485 y 0.51 0.46 0.56
Vaccine side effects 0.90 0.80 0.99 Uniform 10, Estimate
IPD, hospitalized 0.20 0.15 0.25 Uniform 32
IPD, disabled 0.40 0.20 0.60 Uniform 10, Estimate
IPD, invasive pneumococcal disease; PPSV23, 23-valent pneumococcal polysaccharide vaccine; QALY, quality-adjusted life-year.
 Expert panel estimates of PPSV23 effectiveness in the immunocompetent, well, 65-y-old cohort.
y Vaccine side effects include mild redness, swelling, and soreness at the injection site.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 1 – 3 1 7 313introduced childhood 13-valent conjugate vaccine on the elderly
IPD incidence rate and serotype epidemiology. In one-way and
probabilistic sensitivity analyses, IPD incidence, IPD disability,
IPD mortality, vaccine serotype coverage, and percentage of
immunocompromised were varied across triangular distributions
on the basis of maximum variation in values reported by the
Centers for Disease Control and Prevention’s Active Bacterial
Core surveillance network between 2003 and 2010 [1].
Vaccine Effectiveness
Vaccine effectiveness was defined as a function of baseline
vaccine effectiveness, declining effectiveness with time, vaccine
serotype coverage, and the percentage of the population that wasimmunocompromised. PPSV23 was assumed effective only
against IPD [4]. Declines in PPSV23 effectiveness over time and
PPSV23 ineffectiveness in immunocompromised populations
were modeled on the basis of expert panel estimates of PPSV23
effectiveness (Table 2) [15]. There is little evidence that PPSV23
effectiveness varies by race. To evaluate this parameter’s impact,
PPSV23 effectiveness was varied 10% in sensitivity analyses on
the basis of author estimates (Table 2).
Vaccination Program Effectiveness
Based on the current percentage of elderly African Americans
(45%) and Hispanics (40%) reporting having ever received PPSV23
in 2009 and the relative size of those populations, a population-
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Fig. 2 – Cumulative pneumococcal vaccination rates used in
the model. Three scenarios are presented here, each one
assuming that increases in the vaccination rate were driven
by the deployment of a national program to decrease racial
disparities in pneumococcal vaccination rates.
Pneumococcal vaccination rates in Caucasians aged 65
years and older are 65%. PPSV23, 23-valent pneumococcal
polysaccharide vaccine.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 1 – 3 1 7314weighted average of ever having received pneumococcal vaccina-
tion of 43% was calculated [5,12]. In the no-intervention arm, 43%
of the cohort was vaccinated in year 1 with no incremental
increases in years 2 to 10, thus incorporating the entire reported
vaccination uptake for the minority population aged 65 years and
older at age 65 years. This concentrates the benefits of vaccina-
tion in the no-intervention arm to early in the model time frame,
biasing against the intervention arm because of the effects of
discounting and age-related decreases in vaccine effectiveness.
With the intervention program, 51% of the cohort was vaccinated
in year 1 and further incremental increases in annual vaccination
over years 2 to 10 resulted in 65% of the population receiving
PPSV23 by year 10, equaling the current pneumococcal vaccina-
tion rate seen in the elderly Caucasian population (Fig. 2) [5]. In
the base-case analysis, it was assumed that program-associated
increases in vaccination rates were greater earlier in the program
and decreased in later years to reflect decreasing program impact
because of response fatigue and a ceiling effect at higher
vaccination rates (Fig. 2). This rapid increase in vaccination rates
from 43% to 62% in the program’s first 5 years is reasonable given
evidence suggesting that multimodal interventions result in a
median 16% increase in vaccination rates over a single year [16].
The final vaccination rate achieved with the program (65%) is well
within the range of achievable pneumococcal vaccination rates
reported elsewhere for the elderly African American (73%) and
Hispanic (76%) populations [17]. In a secondary analysis, we
evaluated the assumption that program-associated gains in
vaccination rates were linear, still assuming that a vaccination
rate of 65% was reached in year 10. When the program ended at
year 10, the incremental vaccination rate dropped immediately to
zero, with no residual effect of the program, possibly biasing
results against the program. In sensitivity analyses to establish a
range of possible improvements in vaccination rates, minimum
and maximum possible vaccination rates at 10 years of 55% and
75%, respectively, were examined, as shown in Figure 2.
Costs and Effectiveness
The following costs were included in the model: vaccine program
promotion, vaccine dose and administration, vaccine side effect
treatment, IPD hospitalization with and without death, and
annual disability due to IPD (Table 2). No differences in outpatientcare costs between patients who did and did not acquire IPD were
modeled, which could bias against the intervention. Costs were
mainly drawn from the published literature and 2006 Nationwide
Inpatient Sample data. To estimate the costs of a program to
decrease pneumococcal vaccination disparities, conservative
costs from our previous work on the cost-effectiveness of a
similar national vaccination intervention program to ameliorate
disparities in influenza vaccination were used [9]. Briefly, three
cost scenarios for the intervention were assumed: $5, $10 (base
case), and $15 per targeted minority elder per year, regardless of
previous vaccination status. These estimates were based on
previous research suggesting that broad strategies to increase
vaccination rates that are feasible on a national level—patient
reminder interventions, standing order implementations, or
public health education—would individually be unlikely to cost
more than $5 per targeted minority elder per year [18–20].
Programs using multiple strategies to increase vaccination rates
are more effective than single-component strategies [16]. Thus, in
the base-case analysis, it was assumed that the vaccination
intervention program deployed two discrete strategies to increase
the minority elder vaccination rate, at a cost of $5 per targeted
living minority elder per year for each strategy, resulting in a cost
of $10 per targeted minority elder per year. These program costs
are conservative, because they are allocated to every living
minority elder on an annual basis regardless of prior vaccination
status and were chosen to bias results against the intervention.
All costs were kept constant except for intervention program
costs, which were increased 3% annually. All costs are in 2011
dollars.
Effectiveness was measured in quality-adjusted life-years
(QALYs), assuming that QALYs were time spent in a particular
health state multiplied by the utility of that state, with utilities
ranging from 1 (perfect health) to 0 (death) (Table 2). Utility values
are defined by activity limitation and perceived health and are
based on 1990 data from the National Health Interview Survey, a
sample of noninstitutionalized residents in 50,000 US households
[21]. Given the absence of available health status data from
institutionalized residents in correctional facilities, nursing
homes, and long-term care facilities, assumptions were made
regarding activity limitation and perceived health to estimate
utility weights for these populations [21]. All cost and effective-
ness values were discounted at 3% per year in the base case and
3% to 5% in a secondary analysis [10].
Analyses
A cost-effectiveness analysis was performed to determine the
incremental cost-effectiveness ratio (ICER) of the vaccination
program relative to no program. Subsequently, one-way sensitiv-
ity analyses were examined to identify parameters having the
greatest impact on results. Based on preliminary analyses sug-
gesting that the vaccination program cost and vaccination rate
achieved in year 10 had a substantial impact on the ICER, these
parameters were varied in a two-way sensitivity analysis to
estimate threshold values for cost-effectiveness. For one-way
and two-way sensitivity analyses, threshold analyses were per-
formed to determine parameter values that caused the program
ICER to cross $50,000 and $100,000 per QALY gained thresholds.
Three probabilistic sensitivity analyses were performed for the
base-, low-, and high-cost scenarios, with all parameter values
simultaneously varied over distributions (Table 2). To account for
both parameter uncertainty and population heterogeneity in the
probabilistic sensitivity analysis, we stratified the cohort by race,
separately varying the probability of receiving vaccination with
the intervention in elderly African American and Hispanic
populations. For each parameter, the listed range and distribu-
tion mirrors the 95% confidence interval for that parameter,
$0 $50,000 $100,000 $150,000
Vaccination rate in year 10 given program
Cost of program per targeted elder per year
Incidence of IPD
Probability of death given IPD
Baseline vaccine effectiveness
Change in vaccine effectiveness due to race
Incremental cost per QALY gained
75% 55%
$5 $15
-20%+20%
-20%+20%
0.80 0.60
+10% -10%
Fig. 3 – One-way sensitivity analysis. The six parameters presented here, when varied individually across their distributions,
caused a 10% or more change in the ICER of the vaccination intervention program relative to no program. ICER, incremental
cost-effectiveness ratio; IPD, invasive pneumococcal disease; QALY, quality-adjusted life-year.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 1 1 – 3 1 7 315based on data from the reference or from approximations for
ranges. Although $50,000 per QALY gained has been frequently
used as a cost-effectiveness criterion, recent research suggests
that a threshold of $100,000 per QALY is reasonable [22]. Both
criteria were used as lower and upper thresholds for cost-
effectiveness. This study was completed between October 2011
and February 2012.Results
Base-Case Analysis
In the base-case analysis, the national vaccination intervention
program to eliminate disparities in pneumococcal vaccination
rate among elderly minority populations was both more costly
($238 vs. $185) and more effective (9.71249 vs. 9.71131 QALYs
gained) than no program, costing $45,161 per QALY gained. Over
its 10-year duration, in the approximately 396,000 in the 65-year-
old minority birth cohort, the intervention prevented 853 IPD
cases and 134 IPD deaths at a cost of $22.7 million, or $26,626 per
IPD case avoided and $169,027 per IPD death avoided. In the
secondary analysis, in which constant incremental gains in
vaccination rate over the 10-year program period were assumed,
the program cost $52,432 per QALY gained.
One-Way and Two-Way Sensitivity Analyses
In the one-way sensitivity analysis, six individual parameters
resulted in a 10% or more change in the ICER of the vaccination
intervention program relative to no program (Fig. 3). The two
parameters whose variation most affected the ICER were the
vaccination rate in program year 10 ($21,000–$116,000 per QALY)
and program cost ($7,000–$84,000 per QALY). For these two
variables, the ICER was less than $50,000 per QALY when the
year 10 vaccination rate was more than 64.2% or the program cost
was less than $10.63 per person, and was less than $100,000 per
QALY when the vaccination rate was more than 56.4% or theprogram cost was less than $17.12 per person. In the two-way
sensitivity analysis varying both program costs and the year 10
vaccination rate, the ICER was less than $100,000 per QALY when
the program cost less than $8.60 per targeted elder per year and
resulted in a year 10 vaccination rate of more than 62.8%. When
varying vaccination program costs, the ICER varied from 80% to
120% of its original value when the vaccination rate achieved in
year 10 of the program varied between 64.9% and 66.2% in the
low-cost scenario, 63.6% to 67.9% in the base-case scenario, and
63.3% to 68.5% in the high-cost scenario. In secondary analyses,
when the relative incidence of IPD in the elderly African Amer-
ican and Hispanic populations was varied from 80% to 120% of
the base case, the ICER varied from $38,463 to $50,372 per QALY
gained. When the discount rate was increased from 3% to 5%, the
ICER of the vaccination program increased from $45,161 to
$66,270 per QALY gained.
Probabilistic Sensitivity Analysis
Results from the probabilistic sensitivity analysis examining
three different cost scenarios are presented in Figure 4. Com-
pared with no program, the vaccination program had a higher
probability of being cost-effective when program costs were
lower and the societal willingness-to-pay threshold was higher.
At a willingness-to-pay threshold of $50,000 per QALY gained, the
probability of the vaccination intervention program being cost-
effective under the base-, low-, and high-cost scenarios was,
respectively, 64%, 100%, and 1%. At a willingness-to-pay thresh-
old of $100,000 per QALY gained, the probability of the program
being cost-effective under the base-, low-, and high-cost scenar-
ios was, respectively, 100%, 100%, and 79%.Conclusions
This exploratory study outlines the parameters for a cost-
effective vaccination program designed to eliminate known dis-
parities in pneumococcal vaccination among elderly minority
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Fig. 4 – Acceptability curves from probabilistic sensitivity
analyses. Depiction of the likelihood of a pneumococcal
vaccination intervention program being cost-effective at
different costs and willingness-to-pay thresholds. QALY,
quality-adjusted life-year.
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in the base-case scenario ($45,161 per QALY gained). Using
conservative assumptions regarding the cost and effectiveness
of such a vaccination program, the program was cost-effective by
conventional criteria (o$50,000 per QALY gained) and became
cost-prohibitive (4$100,000 per QALY gained) only at relatively
unlikely values for the vaccination rate achieved in year 10 of the
program (o56.4%, compared with 43% prior to year 1 of the
program). This study suggests that a pneumococcal vaccination
program directed at elder minorities is moderately (64%) and
highly (100%) likely to be cost-effective under more and less
conservative cost-effectiveness thresholds, respectively.
This study adds to the wealth of research supporting the cost-
effectiveness of pneumococcal vaccination in elderly populations
and to more recent studies suggesting that national programs to
promote vaccination in elderly populations, in general, and in
elderly minority populations, more specifically, are likely to be
cost-effective [9,20]. In this analysis, the ICER of the minority
pneumococcal vaccination program ($45,161 per QALY gained)
was comparable to the ICER of a similar minority influenza
vaccination program ($48,617 per QALY gained) reported in our
previous work, providing further evidence that vaccination pro-
grams aimed at reducing racial disparities in vaccination rates
are cost-effective [9]. This similarity in the ICERs of influenza and
pneumococcal minority elder vaccination programs is likely the
result of counterbalancing differences in disease incidence and
cost. Influenza is more common but less costly, whereas IPD is
less common but more costly. Beyond suggesting that a pneu-
mococcal vaccination intervention program is likely to be cost-
effective, this study also provides broad guidelines for cost
thresholds required to maintain a cost-effective program.
Findings supporting a minority vaccination intervention pro-
gram are particularly important in the context of the substan-
tially higher IPD incidence seen in many minority groups,
particularly the African American population, in which IPD
incidence has been reported to be greater than twice that seen
in Caucasians [2]. The reasons for this racial difference are likely
multifactorial. Disadvantaged racial groups have higher rates of
substance abuse, including tobacco and alcohol, which are
associated with increased IPD [23]. HIV incidence is also higher
is some minority groups, and HIV is associated with increased
IPD incidence [24]. Race also influences crowding and poverty,
further complicating potential IPD risk factors [25]. Hence, there
are many potential approaches for interventions to reduce racial
disparities in IPD incidence.
Several aspects of this study are worthy of mention. First, the
model incorporates conservative assumptions regarding the costand effectiveness of the vaccination intervention program to bias
the model against it. We assumed that the program deployed two
independent strategies to increase vaccination rates, cost $10 per
targeted minority elder per year regardless of prior pneumococcal
vaccination status, and increased the cumulative minority elder
vaccination rate to 65% to match the elderly Caucasian vaccina-
tion rate by program year 10. Second, no potential ancillary
benefits of the vaccination intervention program, such as con-
comitantly improved vaccination rates in the elderly Caucasian
population, were modeled. Depending on the strategies deployed,
it is possible that a vaccination intervention program targeted
toward minority elders would also have beneficial effects for all
elders. Third, only with relatively large program costs and small
gains in vaccination rates did the program become cost-
prohibitive (ICER4$100,000 per QALY gained).
Several important limitations bear mentioning. First, the model
considered a single birth cohort of minority elders age 65 years
and did not consider multiple birth cohorts age 65 years or more.
Thus, it is not possible to directly generalize our findings to the
entire elderly minority population. Given that IPD incidence and
case fatality increases after age 75 years, however, this modeling
choice is likely to bias the model against the vaccination program.
Second, declines in vaccine effectiveness with time were based on
expert opinion due to the absence of rigorous empirical data. This
parameter, however, was varied widely in sensitivity analyses and
was found to have a relatively small impact (Fig. 3). Third, because
of few data on IPD incidence in the elderly Hispanic population,
IPD incidence was estimated on the basis of relative IPD incidence
in pediatric African American and Hispanic populations [7].
Published epidemiologic data, however, do not suggest large
differences in IPD disease burden across age cohorts between
African American, Caucasian, and ‘‘other’’ populations, and sensi-
tivity analyses suggest a modest impact of this parameter on the
ICER [2]. Fourth, we assumed that the elderly minority population
achieves a vaccination rate that is equivalent to the elderly
Caucasian population rate (65%) by program year 10. If elderly
minority populations, however, are less responsive than elderly
Caucasian populations to strategies aimed at improving vaccina-
tion rates, the program may be less cost-effective than currently
assessed. Given historical distrust of health care providers and
differences in health care–seeking behavior reported among min-
ority populations, this is not an unreasonable concern [26]. From
2000 to 2009, however, absolute increases in pneumococcal vacci-
nation rates in elderly African Americans and Hispanics (13.9%
and 9.7%, respectively) outpaced increases in vaccination rates in
elderly Caucasians (8.1%) [5]. Furthermore, outcomes from an
urban network of 11 federally qualified urban health centers in
Denver have shown pneumococcal vaccination rates in African
American, Hispanic, and Caucasian populations of 73%, 76%,
and 61%, respectively, suggesting that higher pneumococcal
vaccination rates in elderly minority populations are achievable
[17].
This analysis suggests that even with conservative assump-
tions, a national program to reduce disparities in pneumococcal
vaccination rates among elderly minority groups would be cost-
effective. This work has important policy implications, suggest-
ing that up to $10.63 per targeted elder per year can be spent on a
vaccination program targeted at elder minorities and that this
program would remain cost-effective at the $50,000 per QALY
threshold provided there are reasonable gains in the pneumo-
coccal vaccination rate. This analysis will serve as a basis for
future evaluation of specific vaccination program strategies to
increase the vaccination rate among minority elders.
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